Contact Supplier

Contact Supplier

To get in touch with TAmiRNA GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    TAmiRNA to present miND® NextGen sequencing insights to RNA 2023 in Singapore

    news-releasesTAmiRNA GmbH
    May 24th 2023

    Vienna, Austria: Biotech and diagnostic innovator TAmiRNA will be a significant contributor to this year’s RNA Society Annual Meeting in Singapore with two poster presentations.

    These will focus on using its miND® spike-ins to identify novel circulating microRNA Biomarkers of CNS damage, as well as comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs).

    Poster presentations

    TAmiRNA Senior Scientist Dr. Kseniya Khamina-Kotisch will present Poster 46 ‘Identification of novel circulating MicroRNA Biomarkers of Central Nervous System Damage by absolute quantitation using a MicroRNA Next-Generation Sequencing Discovery (miND) Assay’. She will also present Poster 66: ‘Comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs) in cells, plasma, urine, and extracellular vesicles’.

    Both posters will show different aspects of the significance of the development of the miND® Next Generation Sequencing Discovery platform and its spike-in that serves for quality control and absolute normalization. This spike-in allows conversion of read counts to copies/μl total RNA and reduce bias originating from variation in RNA composition between samples.

    NextGen Sequencing Discovery

    Dr. Khamina-Kotisch commented: “I will show how the product consists of seven unique core sequences mixed in specific proportions to cover a wide range of endogenous microRNAs, representing up to 65,536 possible 21 nucleotide (nt) sequences. Each unique core sequence consists of 13 nts that do not match the genome of interest, flanked by a set of four randomized nts on both 5’ and 3’ ends to reduce sequencing bias and ensure precise quantitation of small RNA. Altogether, the miND® spike-ins contains up to 458,752 unique oligonucleotides.

    “The miND®spike-in sequences are detected in the NGS data along with the endogenous small RNAs. Read counts of the miND®spike-in and endogenous miRNAs are used to calculate absolute concentrations (amol/μL or molecules/μL). This conversion can either be achieved by using TAmiRNA’s miND®NGS data pipeline or by incorporating provided scripts in an already established NGS data analysis workflow.”

    About TAmiRNA

    TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. TAmiRNA currently commercialized hepatomiR® under the CE-IVD mark for the diagnosis of liver function in liver cancer patients.

    For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898. For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency.

    More information available at:

    About RNA 2023

    The RNA Society is a non-profit international scientific society with more than 1800 members dedicated to fostering research and education in the field of RNA science.

    The society’s annual meeting forms a platform for the worldwide community of scientists dedicated to advancing understanding of RNA biology to network and share knowledge.

    The 28th RNA Society Annual Meeting (RNA 2023) will be a six-day event opening May 30 at the Suntec Convention Centre in Singapore.

    The meeting will feature keynote presentations from Dr. Britt Glaunsinger, of UC Berkeley and HHMI, USA, Dr. Ramesh Pillai, from University of Geneva, and Dr. Yigong Shi, of China’s Westlake University.

    Conference tracks will cover all significant aspects of RNA technology, including Splicing, Folding, Localization and Transport, Ribosome and mRNA Translation, Modification, RNA-binding Proteins and  Small RNAs.

    The event is primarily organized by the RNA Society in partnership with Australia-based Simple Meetings, with further information at:


    Click on TAmiRNA MiND Next Generation Sequencing  for further information.


    hepatomiR® is a blood-based Biomaker for the Assessment of Live Function before Hepatectomy in patients with HCC, CCC or mCRC

    TAmiRNA to present miND® NextGen sequencing insights to RNA 2023 in Singapore
    TAmiRNA to present miND® NextGen sequencing insights to RNA 2023 in Singapore

    TAmiRNA senior scientist, Dr. Kseniya Khamina-Kotisch, will present insights on miND® technology.

    Contact TAmiRNA GmbH

    Simply fill out the form below to contact TAmiRNA GmbH now.

    Send TAmiRNA GmbH a Message